抗HBV感染的治疗难点之一是安全停药或治疗终点的确定,目前主要依靠血清HBV DNA、HBeAg/抗-HBe、HBsAg/抗-HBs和抗-HBc评估慢性乙型肝炎治疗效果,并以持久的HBsAg清除作为停药标准.但血清HBsAg阴转率很低且难以实现"临床治愈(或功能性治愈)",因此,近年来提出了许多新的指导慢性乙型肝炎患者停药的指标,如肝组织HBV cccDNA、血清HBcrAg和血清HBV RNA.本文就以上指标的研究进展进行综述.%One of the difficulties in chronic hepatitis B (CHB) treatment is to safely withdraw drugs or determine the endpoint of antiviral therapy. At present, serum HBV DNA, HBeAg/anti-HBe, HBsAg/anti-HBs and anti-HBc are major indicators for evaluating the treatment effect of CHB, and persistent HBsAg loss is considered as the standard of drug withdrawal. However, the proportion of serum HBsAg loss is very low and it's difficult to achieve clinical cure or functional cure. The indicators with potential value for evaluation for drug withdrawal in CHB patients, including intrahepatic HBV cccDNA, serum HBcrAg, and serum HBV RNA are developed in recent years. This paper aims to overview the progress of these indicators.
展开▼
